Development of an RT-qPCR and a Next-Generation Sequencing approach to assess viral shedding of NDV-based SARS-CoV-2 variant vaccines
Live-attenuated intranasal vaccines offer great promise to generate mucosal immunity and reduce breakthrough infections after vaccination. In this work, we have developed a combined reverse transcriptase-quantitative polymerase chain reaction and next-generation sequencing-directed approach to assess the viral shedding of multivalent Newcastle disease virus-based severe acute respiratory syndrome coronavirus 2 vaccines. This new formulation will be evaluated as a mucosal booster in phase I clinical trials next year.
Authors
- Weina Sun (ORCID: https://orcid.org/0000-0002-2435-5047)
- Nicholas Lemus (ORCID: https://orcid.org/0009-0006-9055-6513)
- Peter Palese (ORCID: https://orcid.org/0000-0002-0337-5823)
- Stefan Slamanig (ORCID: https://orcid.org/0000-0003-3694-6597)
- William R. Shea
- Tsoi Ying Lai
- Irene González‐Domínguez (ORCID: https://orcid.org/0000-0002-7920-5505)
- Adam Abdeljawad
- Marta Boza (ORCID: https://orcid.org/0009-0003-0015-8676)
Institutions
- University of Amsterdam (NL)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Microbiology Spectrum
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1128/spectrum.00653-25
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00